Wealth Enhancement Advisory Services LLC Acquires 294 Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)

Wealth Enhancement Advisory Services LLC increased its holdings in shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) by 1.4% during the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 22,047 shares of the biopharmaceutical company’s stock after purchasing an additional 294 shares during the period. Wealth Enhancement Advisory Services LLC’s holdings in Ultragenyx Pharmaceutical were worth $928,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently modified their holdings of RARE. Motley Fool Asset Management LLC lifted its holdings in Ultragenyx Pharmaceutical by 0.3% during the third quarter. Motley Fool Asset Management LLC now owns 141,649 shares of the biopharmaceutical company’s stock worth $8,005,000 after buying an additional 360 shares during the period. KBC Group NV lifted its stake in shares of Ultragenyx Pharmaceutical by 24.5% during the 3rd quarter. KBC Group NV now owns 2,568 shares of the biopharmaceutical company’s stock worth $143,000 after purchasing an additional 506 shares during the last quarter. M&T Bank Corp lifted its stake in shares of Ultragenyx Pharmaceutical by 8.1% during the 3rd quarter. M&T Bank Corp now owns 6,992 shares of the biopharmaceutical company’s stock worth $388,000 after purchasing an additional 525 shares during the last quarter. Amalgamated Bank boosted its position in Ultragenyx Pharmaceutical by 13.4% during the second quarter. Amalgamated Bank now owns 5,896 shares of the biopharmaceutical company’s stock valued at $242,000 after purchasing an additional 696 shares in the last quarter. Finally, True Wealth Design LLC purchased a new position in Ultragenyx Pharmaceutical in the third quarter valued at about $43,000. 97.67% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

RARE has been the subject of several analyst reports. Wedbush reissued a “neutral” rating and set a $48.00 price target (up from $46.00) on shares of Ultragenyx Pharmaceutical in a research report on Monday. HC Wainwright reissued a “buy” rating and set a $95.00 target price on shares of Ultragenyx Pharmaceutical in a research report on Tuesday, December 24th. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $77.00 price target on shares of Ultragenyx Pharmaceutical in a report on Wednesday, November 6th. Canaccord Genuity Group reiterated a “buy” rating and set a $121.00 price objective on shares of Ultragenyx Pharmaceutical in a report on Tuesday, November 12th. Finally, JPMorgan Chase & Co. dropped their target price on Ultragenyx Pharmaceutical from $105.00 to $102.00 and set an “overweight” rating on the stock in a research note on Thursday, November 21st. One investment analyst has rated the stock with a hold rating and thirteen have assigned a buy rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $92.29.

Ultragenyx Pharmaceutical Stock Performance

Ultragenyx Pharmaceutical stock opened at $40.98 on Thursday. The business’s 50-day simple moving average is $45.49 and its two-hundred day simple moving average is $49.58. The company has a market cap of $3.78 billion, a PE ratio of -6.33 and a beta of 0.58. Ultragenyx Pharmaceutical Inc. has a fifty-two week low of $37.02 and a fifty-two week high of $60.37.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last released its earnings results on Tuesday, November 5th. The biopharmaceutical company reported ($1.40) EPS for the quarter, topping analysts’ consensus estimates of ($1.45) by $0.05. Ultragenyx Pharmaceutical had a negative return on equity of 187.12% and a negative net margin of 106.93%. The firm had revenue of $139.49 million during the quarter, compared to the consensus estimate of $135.28 million. During the same quarter in the previous year, the company posted ($2.23) earnings per share. The company’s revenue was up 42.3% compared to the same quarter last year. As a group, analysts predict that Ultragenyx Pharmaceutical Inc. will post -6.2 EPS for the current fiscal year.

Insider Buying and Selling

In other Ultragenyx Pharmaceutical news, CEO Emil D. Kakkis sold 11,727 shares of the company’s stock in a transaction on Monday, December 30th. The shares were sold at an average price of $42.23, for a total value of $495,231.21. Following the sale, the chief executive officer now directly owns 2,183,985 shares of the company’s stock, valued at approximately $92,229,686.55. This represents a 0.53 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 5.80% of the stock is currently owned by corporate insiders.

Ultragenyx Pharmaceutical Company Profile

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.